Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care
- PMID: 37204146
- PMCID: PMC10321139
- DOI: 10.1080/15265161.2023.2207500
Rare Disease, Advocacy and Justice: Intersecting Disparities in Research and Clinical Care
Abstract
Rare genetic diseases collectively impact millions of individuals in the United States. These patients and their families share many challenges including delayed diagnosis, lack of knowledgeable providers, and limited economic incentives to develop new therapies for small patient groups. As such, rare disease patients and families often must rely on advocacy, including both self-advocacy to access clinical care and public advocacy to advance research. However, these demands raise serious concerns for equity, as both care and research for a given disease can depend on the education, financial resources, and social capital available to the patients in a given community. In this article, we utilize three case examples to illustrate ethical challenges at the intersection of rare diseases, advocacy and justice, including how reliance on advocacy in rare disease may drive unintended consequences for equity. We conclude with a discussion of opportunities for diverse stakeholders to begin to address these challenges.
Keywords: Bioethics; genetics; health equity; patient advocacy; rare diseases; word.
Comment in
-
The Other Side of the Self-Advocacy Coin: How For-Profit Companies Can Divert the Path to Justice in Rare Disease.Am J Bioeth. 2023 Jul;23(7):88-91. doi: 10.1080/15265161.2023.2207521. Am J Bioeth. 2023. PMID: 37339288 No abstract available.
-
Reliance on Advocacy is the Symptom Not the Disease.Am J Bioeth. 2023 Jul;23(7):86-88. doi: 10.1080/15265161.2023.2207540. Am J Bioeth. 2023. PMID: 37339294 Free PMC article. No abstract available.
-
Addressing the Burdens That Newborn Screening Imposes on Underserved Communities.Am J Bioeth. 2023 Jul;23(7):79-82. doi: 10.1080/15265161.2023.2207542. Am J Bioeth. 2023. PMID: 37339296 Free PMC article. No abstract available.
-
Rare Disease, Advocacy, and Caregiver Burnout.Am J Bioeth. 2023 Jul;23(7):91-94. doi: 10.1080/15265161.2023.2207509. Am J Bioeth. 2023. PMID: 37339297 No abstract available.
-
Whose Genome? Which Genetics?Am J Bioeth. 2023 Jul;23(7):50-53. doi: 10.1080/15265161.2023.2207528. Am J Bioeth. 2023. PMID: 37339304 No abstract available.
-
Ethical Considerations in Clinical Trials for Rare Genetic Diseases: The Case of Huntington's Disease.Am J Bioeth. 2023 Jul;23(7):94-96. doi: 10.1080/15265161.2023.2207511. Am J Bioeth. 2023. PMID: 37339308 No abstract available.
-
Who Is Responsible for Promoting Equity in Rare Disease Research?Am J Bioeth. 2023 Jul;23(7):83-85. doi: 10.1080/15265161.2023.2207512. Am J Bioeth. 2023. PMID: 37339309 No abstract available.
-
Tackling Structural Injustices: On the Entanglement of Visibility and Justice in Emerging Technologies.Am J Bioeth. 2023 Jul;23(7):100-102. doi: 10.1080/15265161.2023.2207514. Am J Bioeth. 2023. PMID: 37339313 No abstract available.
-
Getting It Right: How Public Engagement Might (and Might Not) Help Us Determine What Is Equitable in Genomics and Precision Medicine.Am J Bioeth. 2023 Jul;23(7):5-8. doi: 10.1080/15265161.2023.2215154. Am J Bioeth. 2023. PMID: 37339317 No abstract available.
-
Critiquing the Critique of Advocacy.Am J Bioeth. 2023 Jul;23(7):97-99. doi: 10.1080/15265161.2023.2208073. Am J Bioeth. 2023. PMID: 37339318 Free PMC article. No abstract available.
-
Innovating for a Just and Equitable Future in Genomic and Precision Medicine Research.Am J Bioeth. 2023 Jul;23(7):1-4. doi: 10.1080/15265161.2023.2215201. Am J Bioeth. 2023. PMID: 37353052 Free PMC article. No abstract available.
References
-
- Appleby Julie. 2017a. “Drug Puts A $750,000 ‘Price Tag On Life.’” NPR, August 1, 2017, sec. Treatments. https://www.npr.org/sections/health-shots/2017/08/01/540100976/drug-puts....
-
- –––. 2017b. “Drug Puts A $750,000 ‘Price Tag On Life.’” Kaiser Health News (blog). August 2, 2017. https://khn.org/news/drug-puts-a-750000-price-tag-on-life/.
-
- Arnold Georgianne L., Saavedra-Matiz Carlos A., Galvin-Parton Patricia A., Erbe Richard, Devincentis Ellen, Kronn David, Mofidi Shideh, et al. 2010. “Lack of Genotype-Phenotype Correlations and Outcome in MCAD Deficiency Diagnosed by Newborn Screening in New York State.” Molecular Genetics and Metabolism 99 (3): 263–68. 10.1016/j.ymgme.2009.10.188. - DOI - PubMed
-
- Ballreich Jeromie, Ezebilo Ijeamaka, Banda Abdallah Khalifa Joshua Choe, and Anderson Gerard. 2022. “Coverage of Genetic Therapies for Spinal Muscular Atrophy across Fee-for-Service Medicaid Programs.” Journal of Managed Care & Specialty Pharmacy 28 (1): 39–47. 10.18553/jmcp.2022.28.1.39. - DOI - PMC - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical